In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY 2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity Mazdutide 10mg Loti Labs Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction Associated Steatohepatitis (MASH) Related Fibrosis and Cirrhosis Updates in Medicine Mazdutide (GLP 1 Glucagon Agonist) Cuts Weight by 14% in Obesity Trial Original Article in Bio GLORY 1 Phase 3 Trial (China, N=610) Instagram Mazdutide vs Retatrutide: Which Weight Loss Injection Comes Out On Top? BetteryouRx